US · FATE
Fate Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92131
- Website
- fatetherapeutics.com
Price · as of 2025-12-31
$1.53
Market cap 170.72M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $26.10 | +1,605.88% |
| Intrinsic Value(DCF) | $0.81 | -47.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $46.87 | +2,963.33% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $9.09 | $29.47 | $1.59 | $0.00 | $56.66 |
| 2014 | $5.05 | $28.85 | |||
| 2015 | $1.82 | $0.54 | $0.00 | ||
| 2016 | $4.80 | $33.03 | $2.03 | $0.00 | $0.00 |
| 2017 | $13.17 | $27.66 | $1.16 | $0.00 | $0.00 |
| 2018 | $16.18 | $30.39 | $1.91 | $0.00 | $0.00 |
| 2019 | $29.46 | $46.19 | $155.43 | $0.00 | $0.00 |
| 2020 | $93.99 | $77.32 | $70,591.46 | $0.00 | $0.00 |
| 2021 | $33.55 | $38.98 | $102,064.19 | $0.00 | $0.00 |
| 2022 | $4.88 | $24.12 | $0.00 | $0.00 | $0.00 |
| 2023 | $8.12 | $26.79 | $4.52 | $0.00 | $39.89 |
| 2024 | $1.01 | $27.14 | $0.64 | $0.00 | $109.86 |
| 2025 | $1.50 | $26.10 | $0.35 | $0.00 | $46.87 |
AI valuation
Our deep-learning model estimates Fate Therapeutics, Inc.'s (FATE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $26.10
- Current price
- $1.53
- AI upside
- +1,605.88%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.81
-47.06% upside
Graham-Dodd
—
— upside
Graham Formula
$46.87
+2,963.33% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FATE | Fate Therapeutics, Inc. | $1.53 | 170.72M | +1,606% | -47% | — | +2,963% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| ALEC | Alector, Inc. | $2.43 | 265.24M | +1,084% | -64% | — | +3,751% | -1.59 | 7.43 | 10.82 | -0.06 | -12.24 | 7.43 | 54.09% | -692.83% | -679.16% | -181.56% | 67.31% | -37.54% | 1.18 | — | 3.83 | 3.68 | 0.22 | 1301.00% | -7907.00% | -2037.00% | -80.87% | -2.65 | 84.98% | 0.00% | 0.00% | 17.16% | -0.05 | -0.04 | 0.37 | -4.88 |
| CRBP | Corbus Pharmaceuticals Ho… | $8.57 | 107.43M | — | — | — | — | -1.84 | 0.52 | — | 1.90 | — | 0.52 | 0.00% | — | — | -59.34% | 944.11% | -43.67% | 0.02 | -26.03 | 12.94 | 12.61 | 0.37 | -6431.00% | — | 1577.00% | -56.39% | -3.54 | 809.88% | 0.00% | 0.00% | 28.50% | 1.47 | 1.72 | — | -0.92 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| VOR | Vor Biopharma Inc. | $15.44 | 105.82M | — | — | — | — | -0.59 | 0.71 | — | -0.07 | — | 0.71 | 0.00% | — | — | -94.52% | -282.56% | -66.29% | 0.33 | — | 5.19 | 4.94 | 0.43 | -286.00% | — | -145.00% | -145.39% | -5.35 | -232.90% | 0.00% | 0.00% | 79.21% | -0.07 | -0.09 | — | -5.73 |
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- CEO
- Bahram Valamehr
- Employees
- 181
- Beta
- 2.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.81 ÷ $1.53) − 1 = -47.06% (DCF, example).